Cleveland BioLabs Inc. [NASDAQ: CBLI] stock went on a downward path that fall over -5.23% on Monday, amounting to a one-week price decrease of less than -17.61%. Over the last 12 months, CBLI stock dropped by -9.38%.
The market cap for the stock reached $20.00 million, with 11.35 million shares outstanding and 5.58 million shares in the current float. Compared to the average trading volume of 272.89K shares, CBLI stock reached a trading volume of 1085054 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Guru’s Opinion on Cleveland BioLabs Inc. [CBLI]:
Oppenheimer have made an estimate for Cleveland BioLabs Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on January 24, 2014. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Buy. The new note on the price target was released on March 21, 2013, representing the official price target for Cleveland BioLabs Inc. stock. Previously, the target price had yet another raise to $3, while Oppenheimer analysts kept a Outperform rating on CBLI stock.
The Average True Range (ATR) for Cleveland BioLabs Inc. is set at 0.19, with the Price to Sales ratio for CBLI stock in the period of the last 12 months amounting to 18.18.
CBLI Stock Performance Analysis:
Cleveland BioLabs Inc. [CBLI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.61. With this latest performance, CBLI shares dropped by -13.17% in over the last four-week period, additionally plugging by 95.95% over the last 6 months – not to mention a drop of -9.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CBLI stock in for the last two-week period is set at 35.30, with the RSI for the last a single of trading hit 26.97, and the three-weeks RSI is set at 40.27 for Cleveland BioLabs Inc. [CBLI]. The present Moving Average for the last 50 days of trading for this stock 1.7666, while it was recorded at 1.6080 for the last single week of trading, and 1.4469 for the last 200 days.
Insight into Cleveland BioLabs Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Cleveland BioLabs Inc. [CBLI] shares currently have an operating margin of -212.03. Cleveland BioLabs Inc.’s Net Margin is presently recorded at -237.73.
Reflecting on the efficiency of the workforce at the company, Cleveland BioLabs Inc. [CBLI] managed to generate an average of -$220,582 per employee. Receivables Turnover for the company is 3.53 with a Total Asset Turnover recorded at a value of 0.34.Cleveland BioLabs Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.70.
Cleveland BioLabs Inc. [CBLI] Insider Position Details
There are presently around $1 million, or 3.20% of CBLI stock, in the hands of institutional investors. The top three institutional holders of CBLI stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 289,351, which is approximately -6.816% of the company’s market cap and around 64.39% of the total institutional ownership; VANGUARD GROUP INC, holding 52,592 shares of the stock with an approximate value of $80000.0 in CBLI stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $27000.0 in CBLI stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Cleveland BioLabs Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 8 institutional holders increased their position in Cleveland BioLabs Inc. [NASDAQ:CBLI] by around 45,221 shares. Additionally, 5 investors decreased positions by around 38,178 shares, while 5 investors held positions by with 324,519 shares. The mentioned changes placed institutional holdings at 407,918 shares, according to the latest SEC report filing. CBLI stock had 5 new institutional investments in for a total of 26,167 shares, while 2 institutional investors sold positions of 13,940 shares during the same period.